Lupin snaps up Nanomi for complex injectables as first biosimilar looms
This article was originally published in Scrip
Executive Summary
Lupin's acquisition of the Dutch firm, Nanomi, is expected to drive its ambitions in the complex injectables space, even as the Indian firm appears to be gearing towards the launch of its first biosimilar product on the Indian market.